News
Dr. Braun on the Evolution of Immunotherapy Combinations in RCC
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), and of pathology and urology, Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center, discusses considerations with immuno-oncology (IO)/IO regimens vs IO/TKI regimens in patients with renal cell carcinoma (RCC).
Source: OncLive